Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients


Autoria(s): Ghiorzo, P.; Villaggio, B.; Sementa, A. R.; Hansson, J.; Platz, A.; Nicolo, G.; Spina, B.; Canepa, M; Palmer, J. M.; Hayward, N. K.; Bianchi-Scarra, G.
Contribuinte(s)

F. Gorstein

Data(s)

01/01/2004

Resumo

Little is known about the correlation between the loss of p16 expression and tumor progression in familial melanoma; no systematic study has been conducted on p16 expression in melanocytic tumors from patients carrying germline CDKN2A mutations. We analyzed 98 early primary lesions from familial patients, previously tested for germline CDKN2A status, by quantitative immunohistochemistry using 3 p16 antibodies. We found that p16 expression was inversely correlated with tumor progression and was significantly lower in melanomas,. including in situ lesions, than in nevi. Of other features analyzed, tumor thickness showed the most significant correlation with p16 levels. Lesions from mutation-negative patients displayed combined nuclear and cytoplasmic staining. However, some mutation-positive lesions (ie, G101W, 113insR, M53I, R24P, and 33ins24), including benign nevi, showed nuclear mislocalization, confirming previous studies suggesting that subcellular distribution indicates functional impairment of p16. (C) 2004 Elsevier Inc. All rights reserved.

Identificador

http://espace.library.uq.edu.au/view/UQ:68508

Idioma(s)

eng

Publicador

W. B. Saunders

Palavras-Chave #Pathology #Cdkn2a/p16ink4a #Mutation #Immunohistochemistry #Localization #Familial Melanoma #Nevi #Tumor-cell Proliferation #Cdkn2a Mutation #Cutaneous Melanoma #Suppressor Gene #Invasive Stage #P16(ink4a) #Deletion #Variants #Inactivation #Progression #C1 #321015 Oncology and Carcinogenesis #730108 Cancer and related disorders #1112 Oncology and Carcinogenesis
Tipo

Journal Article